Investment Thesis
Aspire Biopharma is in severe financial distress with negative stockholders' equity of -$11.5M, indicating liabilities exceed assets and the company is technically insolvent. Operating losses of -$17.5M on minimal revenue of $1.9K demonstrate the company is pre-revenue with unsustainable cash burn of -$4.0M annually, consuming its limited cash reserves of $1.9M within months at current burn rates.
ASBPW Strengths
- Gross margin of 45.5% on limited product sales suggests potential unit economics if revenue scales
- Maintains $1.9M in cash providing short-term runway
- Healthcare/biotech sector has potential for significant upside if clinical/regulatory milestones achieved
ASBPW Risks
- Negative stockholders' equity of -$11.5M indicates technical insolvency and high bankruptcy risk
- Current ratio of 0.17x shows severe liquidity crisis with liabilities 5.8x current assets
- Operating cash flow of -$4.0M annual burn rate with only $1.9M cash means 5-6 months of runway remaining
- Negligible revenue of $1.9K indicates company has not achieved commercial traction
- Operating margin of -901,693% reflects massive losses relative to minimal sales base
- No insider purchases in 90 days suggests lack of confidence from management
Key Metrics to Watch
- Cash position and monthly burn rate - critical for survival timeline
- Revenue growth and path to positive unit economics - essential for viability
- Financing activity and debt restructuring announcements - likely necessity for continuation
- Clinical trial progress and regulatory milestones - only potential value driver
- Stockholders' equity trajectory - key indicator of solvency status
ASBPW Financial Metrics
ASBPW Profitability Ratios
ASBPW Balance Sheet & Liquidity
ASBPW 5-Year Financial Trend
5-Year Trend Summary: Aspire Biopharma Holdings, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.
ASBPW Growth Metrics (YoY)
ASBPW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.9K | -$96.9K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ASBPW Capital Allocation
ASBPW SEC Filings
Access official SEC EDGAR filings for Aspire Biopharma Holdings, Inc. (CIK: 0001847345)